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Summary
It is well known that oocytes can reprogram differentiated
cells, allowing animal cloning by nuclear transfer. We have
recently shown that fertilized zygotes retain reprogramming
activities [1], suggesting that such activities might also
persist in cleavage-stage embryos. Here, we used chromo-
some transplantation techniques to investigate whether
the blastomeres of two-cell-stagemouse embryos can repro-
gram more differentiated cells. When chromosomes from
one of the two blastomeres were replaced with the chromo-
somes of an embryonic or CD4+ T lymphocyte donor cell, we
observed nuclear reprogramming and efficient contribution
of the manipulated cell to the developing blastocyst.
Embryos produced by this method could be used to derive
stem cell lines and also developed to term, generating
mosaic ‘‘cloned’’ animals. These results demonstrate that
blastomeres retain reprogramming activities and support
the notion that discarded human preimplantation embryos
may be useful recipients for the production of genetically
tailored human embryonic stem cell lines.
Results and Discussion
Reprogramming by nuclear transfer allows the generation of
animals and embryonic stem (ES) cell lines from somatic cells
[2]. This approach, if successful with human cells, would allow
the production of human stem cell lines from individual
patients for personalized medicine or in vitro modeling of their
condition [3–5]. However, attempts to produce human ES cell
lines by nuclear transfer have thus far been unsuccessful, in
part because of the limited availability of human oocytes.
Reprogramming by nuclear transfer is only successful under
certain specific conditions, making it difficult to source the
appropriate recipient cell types. Reprogramming and embry-
onic development can occur in animals after transfer of
somatic nuclei into oocytes and zygotes in metaphase of the
cell cycle but fail after transfer during interphase [6–8]. Nuclear
transfer into embryonic blastomeres enucleated in interphase
has also been attempted but has failed to demonstrate
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was observed after transfer of inner cell mass nuclei into two-
cell-stage embryos enucleated in interphase [10].
Our results suggest that one key to successful reprogram-
ming is the removal of the recipient cell genome at metaphase
when the nuclear envelope is broken down and chromosomes
are condensed (Figure 1A). This suggests that reprogramming
might also be possible in cell types other than oocytes or
zygotes, if and only if their genome is removed in mitosis. Be-
cause they are relatively large embryonic cells, we first consid-
ered whether the blastomeres in a two-cell mouse embryo
harbored reprogramming activities.
To determine whether blastomeres contained reprogram-
ming activities, we sought to stably but reversibly arrest
them in mitosis for chromosome transfer studies. We isolated
fertilized zygotes from superovulated mice, cultured them
in vitro to the two-cell stage, and then observed the embryos
for entry into the second mitosis. The two blastomeres usually
entered mitosis between 48 and 54 hr after administration of
the hormone trigger for ovulation. Shortly after mitotic entry,
the embryos divided to the four-cell stage. To find the optimal
conditions in which two-cell embryos could be arrested in
mitosis, we cultured them in the presence of several nocoda-
zole concentrations (see Table S1 available online). Mouse
two-cell embryos required nocodazole concentrations similar
to or slightly higher than those required by zygotes for mitotic
arrest [1]. To determine whether cell-cycle arrest was compat-
ible with embryo viability, we released embryos from the
mitotic block and allowed them to develop in vitro to the blas-
tocyst stage. We found that 32 of 35 embryos (91%) reached
the blastocyst stage, indicating that mitotic arrest with noco-
dazole did not significantly compromise later development.
This finding was consistent with previous studies, which also
suggested that a transient arrest in mitosis by nocodazole is
nontoxic to the embryo [11].
When two-cell embryos were treated with 0.1 mg/ml of noco-
dazole, we observed that they formed an irregular and
unstable spindle that was presumably too disorganized to
allow mitotic progression (Figure S1). Although the spindle
was disorganized enough to cause mitotic arrest, it was still
visible under Hoffman modulation contrast optics (Figure 1C).
When these two-cell embryos were further treated with cyto-
chalasin B to depolymerize the actin cytoskeleton, the spindle
complex with attached chromosomes could still be identified
and removed by micromanipulation (Figure 1D). In all cases,
when the spindle was extracted from one of the two blasto-
meres, staining with the DNA dye Hoechst 33342 demon-
strated that the chromosomes were also successfully
removed. We initially removed the chromosomes from only
one of the two blastomeres and left the other blastomere intact
because this would allow a direct comparison of develop-
mental potential between the transferred and the nontrans-
ferred blastomeres.
To optimize chromosome transfer into blastomeres and to
determine whether they contained reprogramming activities,
we arrested mouse ES cells in mitosis with nocodazole and in-
jected their chromosomes into the enucleated blastomere
(Figure 1E; Movie S1). To allow fate mapping of the blastomere
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(A) Stages of development from the unfertilized oocytes to the two-cell-stage embryo. Oocytes in meiosis and zygotes in mitosis are suitable for nuclear
transfer, but zygotes in interphase or even two-cell-stage embryos in interphase are not. Whether two-cell-stage embryos in mitosis can be used for transfer
of a genome from a more differentiated cell is addressed here.
(B) Two-cell-stage embryo in interphase 54 hr post hCG (human chorionic gonadotropin, a hormone stimulating ovulation).
(C) Blastomeres in mitosis 55 hr post hCG.
(D) One blastomere had the genome removed in mitosis.
(E) One of the two blastomeres transferred with mouse embryonic stem (ES) cells expressing histone H2B-cherry.
(F) A four-cell-stage embryo 12 hr posttransfer.
(G) Morula at 28 hr posttransfer, composed of ten cells, six of which are derived from the transferred blastomere.
(H) Blastocyst at 48 hr posttransfer.that had undergone nuclear transplant, we used donor cells
that expressed a histone H2B-cherry fluorescent fusion
protein. The descendants of the nuclear transfer blastomere
all possessed red fluorescent chromosomes and nuclei, allow-
ing their identification within the embryo (Figures 1E–1H).
Upon release from mitotic arrest, both the transferred and
the unmanipulated blastomeres completed mitosis, and the
embryos cleaved to the four-cell stage. As expected, two cells
within the embryo displayed H2B-cherry fluorescence, indi-
cating that they carried the donor cell chromosomes (Fig-
ure 1F). We found that these four-cell embryos continued to
develop efficiently in vitro to both the morula and blastocyst
stages (Figures 1G and 1H; Table 1).To exclude the possibility that this development depended
on the presence of the nonmanipulated blastomere, we gen-
erated embryos that were derived entirely from the donor
genome. To do so, we fused the two blastomeres at the two-
cell stage, which resulted in a tetraploid two-cell-stage
embryo (Figure 2A). At mitosis, the tetraploid genome was
removed and replaced by a diploid genome of an ES cell.
These manipulated embryos cleaved to the two-cell stage
(27 of 50, or 54%) and efficiently proceeded in development
to the blastocyst stage (21 of 27, or 78%). All nuclei of both tro-
phectoderm and inner cell mass (ICM) expressed H2B-cherry,
indicating that they were derived entirely from the injected
donor chromosomes (Figure 2B). Cavitation of the blastocyst
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Donor Cell Cells Manipulated
Cells Cleaved to Four-Cell Stage
(% of Cells Manipulated)
Morulae 4 Days
Post hCG
Blastocysts with Contribution
from Transferred Blastomere
4 Days Post hCG (% of Cells
Cleaved)
Embryonic stem cell 294 223 (76%) 48 111 (50%)
CD4+ T lymphocyte (>92% pure
population)
90 44 (49%) 23 8 (18%)
hCG indicates human chorionic gonadotropin.is mediated by the expression of a set of novel genes including
those encoding a Na/K-ATPase and aquaporin, which drive
the movement of water across the trophectoderm cell layer
to form a fluid-filled blastocoel [12]. Therefore, the ES donor
cell had clearly been reprogrammed to express a set of novel
genes to form a functional cell type.
If the blastomere were able to reprogram the ES cell chro-
mosomes, then the cells descended from the chromosome
transfer blastomere might be expected to give rise to both
the ICM, from which ES cells are derived, and the trophecto-
derm, which ES cells cannot normally generate. If reprogram-
ming activities are no longer present in the mitotic cytoplasm
of blastomeres, then blastomeres receiving ES cell chromo-
somes might contribute only to the ICM. To determine therelative contribution of the transferred blastomere to the tro-
phectoderm and ICM, we stained blastocysts with the DNA
dye Hoechst 33342 and antibodies specific to the ICM-specific
protein Oct4 (Figure 3A). Following staining, the number of red
fluorescent cells in both the Oct4-positive (ICM) and Oct4-
negative (trophectoderm) compartments was determined
(Figure 3B). We observed that in all blastocysts (11 of 11),
the chromosome transfer blastomere contributed to both the
ICM and trophectoderm, indicating that cellular reprogram-
ming from an ES cell to trophectoderm identity had been al-
lowed to occur. We further reasoned that if the reprogramming
activities of the two-cell embryo were weaker or diminished,
then the transferred blastomere might preferentially give rise
to the ICM. However, we found no statistical evidence forFigure 2. Development after Transfer into a Fused Two-Cell-Stage Embryo
(A) Schematic representation of the experiment. Two-cell-stage embryos are fused at interphase to form a tetraploid one-cell-stage embryo. These chro-
mosomes will assemble into a spindle at the next mitosis, which can be removed and replaced with a diploid genome.
(B) These embryos then cleave and develop to the blastocyst stage.
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(A) Contribution of cells derived from the transferred blastomere marked by H2B-cherry to inner cell mass (ICM) and trophectoderm lineages at the blas-
tocyst stage. Oct4 and H2B-cherry double-positive cells are marked with white asterisks in the third image.
(B) Quantification of H2B-cherry cells in trophectoderm and ICM (red bars). Total number of cells is indicated above each column. The total number of Oct4-
positive cells as a marker of ICM fate is 23% (blue bar) at the expanded blastocyst stage. Error bars indicate standard deviations.
(C) Contribution to full-term development of blastomeres transferred in mitosis.
(D) Contribution of cells derived from transferred (red) and nontransferred (dark) blastomere to a portion of the intestinal tube and the lung.
(E) Stem cells derived from chimeric blastocysts. p1 = passage 1 after manual picking of the ICM outgrowth.
(F) Oct4 expression in ES cells derived after chromosome transfer, alkaline phosphatase staining, and SSEA-1 expression.
(G) Karyotype of stem cells, showing a normal mouse karyotype of 40 chromosomes. Each chromosome is designated with an arbitrary letter of A–AN.
(H) Chimeric mice after injection of ES cells into BDF2 blastocysts. Red fluorescent tissue and agouti (brown) coat are derived from ES cells.such a bias. Fifty percent of trophectoderm cells and forty-
three percent of ICM cells in the blastocyst were derived
from the nuclear transfer blastomere (Figure 3B). In addition,
and overall, we found that the total number of cherry-positive
cells derived from the manipulated blastomere was very
similar or equal to the total number of cells from the untouched
blastomere. This result suggests that the chromosome trans-
fer method had little effect on the overall proportion of cells
that the two blastomeres contributed to the blastocyst and
that reprogramming was relatively complete.
To test whether the chromosome transfer blastomere could
further contribute to development after implantation, we trans-
ferred blastocysts to pseudopregnant recipient females, al-
lowed the embryos to be carried to term, and then assessed
chimerism in the resulting offspring. In these experiments,
the recipient embryos were isolated from a mouse strain with
a black coat color, whereas the donor cells were derived
from a strain with an agouti (brown) coat. We performed
embryo transfer with a total of 111 blastocysts that displayed
red fluorescence and therefore had significant contribution
from the nuclear transfer blastomere. After embryo transfer,
a total of seven pups were delivered by cesarean section, all
of which survived to adulthood. Respiratory failure as seen
after nuclear transfer into oocytes or zygotes was not
observed [1, 13]. Five of these seven mice had a black coat
color, suggesting that they were predominantly or entirely
derived from the unmanipulated recipient blastomere. How-
ever, in the sixth animal, 30% of the coat was agouti, and inthe seventh animal, the coat color was exclusively agouti
(Figure 3C). The agouti coat color in these two animals indi-
cated that that they were chimeric ‘‘cloned’’ animals com-
posed of both reprogrammed and normal cells.
To determine whether cells carrying the donor-cell genome
had contributed widely to the development of the two chimeric
‘‘cloned’’ animals, histological analysis was performed. We
found that red fluorescent cells of donor origin contributed
significantly to the lungs, intestine, and skin (Figure 3D). These
results demonstrate that cells reprogrammed by blastomere
nuclear transfer not only can contribute significantly to the
developing embryo but also are not necessarily outcompeted
by normal embryonic cells.
Since the inception of in vitro fertilization, more than 400,000
embryos have been placed in frozen storage by couples
undergoing assisted reproduction treatment [14]. Recent
studies suggest that the vast majority of these embryos remain
in storage even though they are no longer needed for repro-
ductive purposes. Furthermore, 60% of the couples control-
ling the disposition of these embryos would prefer to have
them donated for stem cell research rather than see them
donated to another couple or simply discarded [15]. Although
a small percentage of human embryos are frozen at the
one-cell stage, a majority of embryos are frozen during the
cleavage stage of preimplantation development. Therefore, if
methods for reprogramming somatic cells via chromosome
transfer into blastomeres could be perfected, a conservative
estimate would suggest that more than 100,000 embryos
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tempts. However, if blastomere nuclear transfer is to be useful
for the production of genetically tailored human ES cell lines,
then it must be shown that ES cell lines can be derived from
blastocysts that result from this approach, and it must be
demonstrated that blastomeres can reprogram terminally
differentiated adult cells.
To determine whether ES cell lines could be derived from
embryos created by blastomere chromosome transfer, we
placed 14 chimeric blastocysts in culture on mouse embryonic
fibroblasts for attempts at ES cell line derivation. Each of the
embryos adhered to the feeder layer, and seven gave rise to
ICM outgrowths. We found that attachment sites and ICM
outgrowths consisted of both red fluorescent cells derived
from the nuclear transfer blastomere and nonfluorescent cells
derived from the unmanipulated blastomere (Figure 3E). Six of
the seven blastocysts gave rise to ES cell cultures, and three of
these contained ES cells derived from both the chromosome
transfer blastomere (cherry-positive colony) and the unmanip-
ulated blastomere (cherry-negative colony) (Figure 3E). When
red fluorescent colonies in these cultures were manually
picked and expanded into pure cultures, polymerase chain
reaction confirmed that they contained the donor genome.
Furthermore, nuclear transfer ES cell lines expressed the plu-
ripotency transcription factor Oct4 (Figure 3G) and contained
a normal karyotype of 40 mouse chromosomes (Figure 3F).
When injected into blastocysts, these ES cells gave rise to
chimeric mice (Figure 3H).
We next sought to demonstrate that the blastomeres of the
two-cell-stage embryo could reprogram a terminally differenti-
ated adult cell. T lymphocytes are terminally differentiated
Figure 4. Blastomeres Can Reprogram Terminally Differentiated
T Cells
(A) Mitotic CD4+ T cell population. Donor T cells do not show expres-
sion of an Oct4::GFP transgene. The arrow points to a mitotic cell.
(B) Developmental progression to the blastocyst stage. Upon trans-
fer of a mitotic T cell into a blastomere in mitosis, development
occurs and theOct4::GFP transgene is reactivated within hours after
transfer.
cells, which can be reprogrammed, but only at a very
low efficiency [16, 17]. We therefore chose T lympho-
cytes as donor cells because they would provide a strin-
gent assay for reprogramming. To assess reprogram-
ming of the T cell genome, we used donor cells
carrying a transgenic reporter in which regulatory
sequences from the Oct4 gene control expression of
GFP (Oct4::GFP). This transgene is not expressed in
somatic tissues, which are therefore nonfluorescent.
However, recent reprogramming studies with defined
transcription factors, cell fusion, and nuclear transfer
have each demonstrated that reactivation of the
Oct4::GFP reporter is a rigorous indicator of complete
reprogramming [1, 18-20].
CD4+ T cells were isolated from the spleen and lymph
nodes of transgenic Oct4::GFP mice as described previ-
ously [21]. Fluorescence-activated cell sorting analysis
of these preparations confirmed that more than 92% of
the cells were indeed CD4+ T lymphocytes. For T cell
chromosome transfer, cultures of purified T cells were
stimulated to enter mitosis with antibodies directed
against CD33 and CD28 and arrested there with
nocodazole. Like other somatic cells, T cells did not express
Oct4::GFP (Figure 4A). As with ES donor cells, we found that
mitotic T cell chromosomes could be readily transferred into
embryonic blastomeres at the two-cell stage. Following chro-
mosome transfer, embryos efficiently underwent cleavage and
could develop to the blastocyst stage (Table 1). Twenty hours
after chromosome transfer, we found that 24 of 67 embryos
developed to the six- to eight-cell stage and that 24 of 24
(100%) of these embryos contained cells expressing GFP.
Oct4::GFP expression indicated that these cells carried the
T cell donor chromosomes and that these chromosomes had
been successfully reprogrammed (Figure 4B). After chromo-
some transfer, we found thatOct4::GFP continued to be highly
expressed within a subset of cells in morula-stage and blasto-
cyst-stage embryos, indicating that reprogramming was
stable (Figure 4B).
In summary, our chromosome transfer studies demonstrate
that reprogramming activities persist in the blastomeres of
cleavage-stage embryos and that these activities are sufficient
to allow the derivation of ES cell lines, the generation of
chimeric ‘‘cloned’’ animals, and the reprogramming of termi-
nally differentiated nuclei. This is a particularly interesting
finding because the proteins and transcripts within the two-
cell blastomeres, just before their mitotic division to the four-
cell stage, are substantially different from those present in
either the fertilized zygote or oocyte [22, 23]. We found that
Oct4::GFP was reactivated within 20 hr following lymphocyte
chromosome transfer at roughly the same time and stage
that it would have been activated in a normally fertilized
embryo. Taken together, these results imply that the blasto-
meres of a two-cell embryo can reprogram the incoming donor
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mere. The reprogrammed cell then goes forward from that
developmental stage rather than reverting to some more prim-
itive oocyte- or zygote-like transcriptional program before
proceeding.
The finding that oocytes, zygotes, embryonic blastomeres,
and ES cells can each reprogram differentiated cells indicates
that reprogramming activities persist through preimplantation
development. When our results are combined with the recent
observations that cell-type-specific transcription factors can
mediate reprogramming [24, 25], this suggests that if the
proper nuclear or chromosome transfer method could be de-
veloped, almost any cell might be reprogrammed into another.
In fact, it may be that the reprogramming activities in a partic-
ular cell type are one and the same with the transcription
factors that specify its identity [26].
The generation of human ES cell lines by nuclear transfer is
still a high priority. Only isogenic cell lines produced by various
reprogramming approaches will allow the effectiveness and
utility of the different methods to be accurately compared.
Our results with mouse embryos suggest that cleavage-stage
human embryos are an important unexplored resource for
nuclear transfer studies. Human embryos are commonly fro-
zen at the four- to eight-cell stage. Importantly, a single blas-
tomere from a four-cell human embryo is roughly the same
size as a mouse zygote, and a blastomere from a human
eight-cell embryo is similar in diameter to a blastomere from a
two-cell mouse embryo. Thus, micromanipulation approaches
similar to those described in this study may be feasible with
the most readily available discarded human embryos. Sourc-
ing this material for nuclear transfer studies will be consider-
ably more routine than obtaining fresh human oocytes, or
even frozen zygotes.
Experimental Procedures
Our method largely followed the protocol of chromosome transfer into
mitotic mouse zygotes described in [1]. Briefly, zygotes were collected
from mated BDF1 females 20–24 hr post hCG (human chorionic gonado-
tropin, a hormone stimulating ovulation) and cultured to the two-cell stage.
Forty-eight to fifty hours post hCG, two-cell-stage embryos were cultured in
the presence of 0.2 mg/ml nocodazole to arrest them in mitosis. For removal
of the donor cell genome, mouse embryos were placed on the heated stage
of a microscope in HCZB with slightly lower nocodazole concentrations
(0.02–0.04 mg/ml) and a high cytochalasin B concentration (w10 mg/ml) to
maximize fluidity of the cytoplasm. Under these low nocodazole concentra-
tions, mouse blastomeres arrest in mitosis with a spindle (Figure S1) that
can conveniently be removed (Movie S1). Enucleation and transfer of
a new genome were performed between 50 and 57 hr post hCG (Movie
S1). The posttransfer survival rate was 136 of 244 (56%). After manipulation,
embryos were cultured in at 37C in 5% CO2. Male ES cells transgenic for
pCAGGS:H2B-cherry were used as donors.
Equipment used consisted of a Nikon microscope equipped with a Narish-
ige micromanipulator. Details of the microscope setup were essentially as
after nuclear transfer into mouse oocytes [27].
Mouse blastocysts were stained with Oct4 antibody (Santa Cruz, sc-5279)
at a dilution of 1:200. Cell numbers were quantified with the Imaris program.
CD4+ T cells were isolated as described previously [21]. Briefly, total sple-
nocytes and lymph node cells were harvested from 6- to 10-week-old
B6jcBA-Tg(Pou5fI-EGFP)2Mnn/J or H2B-GFP transgenic mice. The cells
were labeled with an antibody cocktail consisting of antibodies against
CD8, CD11b, CD45R/B220, CD49b, and TER-119 (IMag Mouse CD4 T
Lymphocyte Enrichment Set – DM, BD Pharmingen). In order to enrich for
CD4+ T cells, negative selection was performed. Labeled cells were magnet-
ically depleted according to the supplier’s protocol. The negative selection
was performed a second time on the enriched fraction in order to increase
the purity of CD4+ T cells. Final CD4+ T cell purity was higher than 92%, and
the patterns of flow cytometry to check for quality of the enrichment wereconsistent with the data shown in the supplier’s technical data sheet. Iso-
lated CD4+ T cells were grown in suspension culture in six-well plates
with a density of 1 million cells per well in 5 ml/well of complete RPMI
medium. The plates were precoated with 1 mg/ml of each of anti-CD33
and anti-CD28 antibodies to stimulate expansion of T cells. One to three
days after culture, T cells were at maximal rates of proliferation and were ar-
rested in mitosis by incubation with 0.1 mg/ml nocodazole for 8 hr. Mitotic
T cells (1%–10% of all T cells) were selected for transfer into blastomeres.
Experiments with animals were performed in accordance with the guide-
lines established by the Harvard University Faculty of Arts and Sciences
Institutional Animal Care and Use Committee for the humane care and use
of animals in research.
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